Research Repository
Technical articles for EU pharmaceutical professionals on peptide CDMO sourcing, preclinical workflows, and regulatory compliance.
Two consensus documents published in the last days of July set perioperative and reproductive guidance for incretin-based therapy, both stating plainly that the underlying evidence is too thin for graded recommendations.
A randomised protocol published in late July sets gradual semaglutide dose reduction over 16 weeks against abrupt cessation, with body weight change as the primary outcome — one of six semaglutide readouts landing in a single week.
A 50-participant phase 2 trial missed its primary craving endpoint but reduced heavy drinking days, drinks per drinking day and cannabis use days — one of several late-July GLP-1 readouts pushing the class past metabolic endpoints.
Registry entries and journal reports posted in late July 2026 put semaglutide into prostate cancer surgery and cognition studies, map where GIPR agonism and antagonism act in the brain, and document tirzepatide-specific hypersensitivity.
